首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1542932

全球排卵测试套件市场 - 2024-2031

Global Ovulation Testing Kits Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球排卵测试套件市场在 2023 年达到 31.5 亿美元，预计到 2031 年将达到 52.9 亿美元，2024-2031 年预测期间复合年增长率为 6.7%。

排卵测试套件也称为排卵预测测试 (OPK)，是一种家用设备，旨在检测女性尿液中是否存在黄体生成素 (LH)。 LH 水平在排卵前不久飙升，标誌着女性试图怀孕的最容易受孕的时间。透过识别 LH 激增，这些套件可协助使用者确定理想的性交时间，以提高受孕的可能性。

排卵是月经週期中最容易受孕的时期，LH 激增通常会在卵子从卵巢释放前 1-2 天发生。黄体生成素 (LH) 排卵检测试剂盒是一种侧流免疫测定法。它们需要尿液样本，有三种形式：试纸、盒式和中流式。

市场动态：

司机

生育障碍发病率上升和技术进步

全球排卵测试套件市场的需求是由多种因素所驱动的。多囊性卵巢症候群 (PCOS) 等生育障碍的发生率不断上升，导致对排卵检测试剂盒的需求增加。这些套件可以帮助患有此类疾病的女性有效追踪她们的月经週期。

多囊性卵巢症候群 (PCOS) 是一种常见的内分泌疾病，影响相当多的育龄妇女，全球盛行率在 5% 至 20% 之间。这种情况的特征是荷尔蒙失衡，可能导致各种症状，例如月经週期不规则、不排卵（不排卵）和多囊性卵巢。这些症状可能导致不孕，使多囊性卵巢症候群成为女性生殖挑战的主要原因之一。

测试技术的不断创新，特别是连接到智慧型手机应用程式的数位排卵套件的开发，正在显着改善追踪生育能力的用户体验。数位排卵试剂盒通常利用先进的演算法和技术来提供更精确的荷尔蒙水平读数，特别是在排卵前激增的黄体生成素 (LH)。例如，Premom 定量排卵测试等套件可以量化 LH 水平并以清晰的数位格式呈现，让使用者更了解自己的荷尔蒙波动。这种高精确度（通常约为 97%）对于月经週期不规则或多囊性卵巢症候群 (PCOS) 等疾病的女性特别有益。

此外，併购、金融投资和关键开发等关键参与者策略将推动该市场的成长。例如，2022年3月，Ro透过收购Dadi（专门从事男性生育和精子检测的公司）而引起关注，作为其向生育服务策略扩张的一部分。此次收购旨在增强 Ro 在生育领域的产品和服务，使该公司能够向客户提供更全面的产品和服务。

此外，2023 年 11 月，医疗科技新创公司 Inito 获得了由 Fireside Ventures 领投的 600 万美元 A 轮融资，Inito 是一家帮助女性在家中快速追踪生育激素的医疗技术新创公司。该公司的生育监测仪和套件只需 10 分钟即可在智慧型手机上为用户提供易于理解的诊断结果。

此外，政府措施（例如意识计划和主要参与者对生殖健康的认可）也推动了该市场的成长。例如，2023 年 11 月，Premom Easy@Home 排卵试纸被着名网站 The Bump 在其年度 Best of The Bump Awards 中评为 2023 年最佳排卵试纸。该活动涉及针对新父母和有抱负的父母对各种婴儿和怀孕产品进行彻底测试。 Easy@Home 排卵试纸在准确性、用户友善性和成本效益方面表现出色，使其成为生殖健康市场的领先选择。

限制

套件成本高昂、缺乏熟练的专业人员、人们的意识有限以及资料隐私问题等因素预计将阻碍市场的发展。

细分市场分析

全球排卵测试套件市场根据产品类型、分销管道和地区进行细分。

尿液排卵测试部分约占全球排卵测试套件市场份额的63.5%

尿液排卵测试预计将在预测期内占据最大的市场份额。尿液排卵测试因其在检测排卵前黄体生成素 (LH) 激增方面的有效性而得到认可。这种准确度对于试图怀孕的女性至关重要，因为它使她们能够确定她们的最佳受孕日。

尿液排卵测试套件专为方便家庭使用而设计，提高了女性的可及性。它们有多种格式，包括试纸、试纸盒和中游测试，使用户能够选择最适合自己喜好和需求的选项。

此外，该行业的主要参与者推出的创新产品和技术进步将推动该市场的成长。例如，2022 年 9 月，新加坡医疗设备和电器製造商 BUZUD 宣布推出 LH 排卵快速检测试剂盒用于自我检测。该测试旨在检测尿液中的黄体生成素 (LH)，该激素在排卵前激增，帮助女性确定她们最容易受孕的日子。 BUZUD LH 排卵快速测试套件的准确度超过 99%，为那些希望怀孕或更好地了解月经週期的人们提供了可靠的解决方案。这些产品在新加坡的推出标誌着女性健康和生育追踪领域的重要发展。

同样，2023 年 5 月，消费品公司 Fridababy, LLC 宣布推出新的生育产品系列。该系列产品包括排卵预测测试、家庭授精套件以及用于追踪排卵和怀孕测试的套件。排卵预测测试的设计价格实惠且用户友好。

此外，合作伙伴关係和协作等关键参与者策略将推动该细分市场在该市场的成长。例如，从 2023 年 7 月开始，希望组建或扩大家庭的女性现在可以透过 questhealth.com 取得 Proov 确认 PdG 家庭收集套件以进行生育力评估。该套件是 Quest Diagnostics 的消费者发起的测试部门与 Proov（专门从事家庭生育和荷尔蒙测试的公司）合作的成果。 Proov 确认 PdG 测试因其是第一个也是唯一一个经 FDA 批准的家庭测试套件而闻名，旨在透过测量黄体酮代谢物 (PdG) 来确认成功排卵。

市场地域占有率

北美约占全球排卵检测试剂盒市场份额的43.5%

由于荷尔蒙失衡和生活方式因素等生育相关挑战的增加，预计北美地区将在预测期内占据最大的市场份额，这加剧了对可靠排卵监测工具的需求。此外，多囊性卵巢症候群（PCOS）的高发生率影响了相当多的育龄妇女，这也大大促进了需求的增加。

蓝牙连接和智慧倒数功能等先进功能的引入推动了对排卵测试套件不断增长的需求。女性对生殖健康和生育管理的认识不断提高，推动了排卵检测试剂的使用。

此外，大量关键参与者的存在、产品发布、合作伙伴关係和协作将推动该地区的市场成长。例如，2023 年 8 月，在美国，家庭怀孕和生育测试领域的领先品牌可丽蓝 (Clearblue) 正在扩展到更年期类别，推出了新的可丽蓝 (Clearblue) 更年期阶段指示器。这个突破性的产品是第一个也是唯一一个可以透过结合尿液 FSH 测量值与年龄和月经週期历史来确定女性可能的更年期阶段的家庭测试。

可丽蓝旨在透过为女性提供追踪更年期进展的工具并与她们的医疗保健提供者进行知情对话来赋予女性权力。 Clearblue 更年期阶段指示器将测试结果安全地储存在免费的更年期阶段 - Clearblue me 应用程式上。透过每隔一天进行五次尿液 FSH 测试，该应用程式可以确定女性可能的更年期阶段。

同样，2022 年，领先的数位排卵测试套件生产商 Sugentech 与 CGETC, Inc.（一家专门从事消费者履行和行销服务的美国公司）建立了策略合作伙伴关係。市面上有各种配备先进功能的数位设备，例如蓝牙连接和智慧倒数功能。该领域的知名品牌包括 Clearblue、First Response 和 EPT

Ovulation testing kits, also referred to as ovulation predictor tests (OPKs), are at-home devices designed to detect the presence of luteinizing hormone (LH) in a woman's urine. LH levels spike shortly before ovulation, marking the most fertile time for women attempting to become pregnant. By identifying this LH surge, these kits assist users in determining the ideal time for sexual intercourse to enhance the likelihood of conception.

Ovulation is the most fertile period of the menstrual cycle, and an LH surge will often occur 1-2 days before an egg is released from the ovary. The luteinizing hormone (LH) ovulation test kit is a lateral flow immunoassay. They require a urine sample and are available in three forms: test strip, cassette, and midstream.

Market Dynamics: Drivers

Rising incidence of fertility disorders and technological advancements

The demand for the global ovulation testing kits market is driven by multiple factors. Rising incidence of fertility disorders such as conditions such as polycystic ovary syndrome (PCOS) are becoming more prevalent, leading to a higher demand for ovulation testing kits. These kits help women with such disorders track their cycles effectively.

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder that impacts a considerable number of women of reproductive age, with global prevalence rates ranging from 5% to 20%. This condition is marked by hormonal imbalances that can result in various symptoms, such as irregular menstrual cycles, anovulation (the failure to ovulate), and the presence of polycystic ovaries. These symptoms can lead to infertility, positioning PCOS as one of the primary causes of reproductive challenges among women.

Continuous innovations in testing technology, particularly the development of digital ovulation kits that connect to smartphone applications, are significantly improving the user experience for those tracking fertility. Digital ovulation kits often utilize advanced algorithms and technology to provide more precise readings of hormone levels, specifically luteinizing hormone (LH), which surges before ovulation. For instance, kits like the Premom Quantitative Ovulation Test can quantify LH levels and present them in a clear, numerical format, allowing users to understand their hormonal fluctuations better. This high accuracy-often around 97%-is particularly beneficial for women with irregular cycles or conditions like polycystic ovary syndrome (PCOS).

Moreover, key player strategies such as mergers & acquisitions, financial investments, and key developments would propel this market growth. For instance, in March 2022, Ro gained attention by acquiring Dadi, a company specializing in male fertility and sperm testing, as part of its strategic expansion into fertility services. This acquisition aims to enhance Ro's offerings in the fertility sector, enabling the company to provide a more comprehensive array of products and services to its clients.

Also, in November 2023, Inito, a medical technology startup that enables women to quickly track fertility hormones at home, secured $6 million in Series A funding led by Fireside Ventures. The company's fertility monitor and kit provide users with easy-to-understand diagnostic results on their smartphones in just 10 minutes.

In addition, government initiatives such as awareness programs and key players' recognition in reproductive health drive this market growth. For instance, in November 2023, Premom Easy@Home ovulation test strips were recognized as the 2023 Best Ovulation Test Strips by the reputable site The Bump during its annual Best of The Bump Awards. This event involves thorough testing of various baby and pregnancy products aimed at new and aspiring parents. The Easy@Home ovulation strips excelled in accuracy, user-friendliness, and cost-effectiveness, establishing them as a leading choice in the reproductive health market.

Restraints

Factors such as the high costs of kits, lack of skilled professionals, limited awareness among people, and Data privacy concerns are expected to hamper the market.

Market Segment Analysis

The global ovulation testing kits market is segmented based on product type, distribution channels, and region.

The urine ovulation tests segment accounted for approximately 63.5% of the global ovulation testing kits market share

The urine ovulation tests segment is expected to hold the largest market share over the forecast period. Urine ovulation tests are recognized for their effectiveness in detecting the surge of luteinizing hormone (LH) that happens right before ovulation. This level of accuracy is essential for women attempting to conceive, as it enables them to pinpoint their peak fertile days.

Urine ovulation test kits are designed for convenient at-home use, enhancing their accessibility for women. They are available in diverse formats, including test strips, cassettes, and midstream tests, enabling users to select the option that best fits their preferences and needs.

Moreover, key players in the industry have innovative launches and technological advancements that would propel this market growth. For instance, in September 2022, BUZUD, a Singapore-based manufacturer of medical devices and appliances, announced the launch of their LH Ovulation Rapid Test Kits for self-testing. The test is designed to detect luteinizing hormone (LH) in urine, which surges before ovulation, helping women identify their most fertile days. With over 99% accuracy, the BUZUD LH Ovulation Rapid Test Kits offer a reliable solution for those looking to conceive or better understand their menstrual cycles. The launch of these products in Singapore marks an important development in women's health and fertility tracking.

Similarly, in May 2023, Fridababy, LLC, a consumer goods company, announced the introduction of a new line of fertility products. This line features an ovulation prediction test, an at-home insemination kit, and a set for tracking ovulation and pregnancy tests. The ovulation prediction test is designed to be affordable and user-friendly.

In addition, key player strategies such as partnerships & collaboration would propel this segment's growth in this market. For instance, in July 2023, Women looking to begin or expand their families can now obtain the Proov Confirm PdG home collection kit for fertility assessment through questhealth.com. This kit is a result of a collaboration between Quest Diagnostics' consumer-initiated testing division and Proov, a company specializing in at-home fertility and hormone tests. The Proov Confirm PdG test is notable for being the first and only FDA-cleared home test kit designed to confirm successful ovulation by measuring the progesterone metabolite (PdG).

Market Geographical Share

North America accounted for approximately 43.5% of the global ovulation testing kits market share

North America region is expected to hold the largest market share over the forecast period owing to the rise in fertility-related challenges, such as hormonal imbalances and lifestyle factors, which have intensified the demand for reliable ovulation monitoring tools. In addition, the high incidence of Polycystic Ovary Syndrome (PCOS), which impacts a considerable number of women of reproductive age, significantly contributes to this increased demand.

The rising demand for ovulation test kits is fueled by the introduction of advanced features like Bluetooth connectivity and smart countdown functions. The rising awareness of reproductive health and fertility management among women is fueling the uptake of ovulation testing kits.

Moreover, a major number of key player's presence, product launches, partnerships & collaborations would drive this market growth in this region. For instance, in August 2023, in the U.S., Clearblue the leading brand in home pregnancy and fertility tests, is expanding into the menopause category with the launch of its new Clearblue Menopause Stage Indicator. This groundbreaking product is the first and only at-home test that can determine a woman's likely menopause stage by combining her urine FSH measurements with her age and cycle history.

Clearblue aims to empower women by providing them with a tool to track their menopause progression and have informed conversations with their healthcare providers. The Clearblue Menopause Stage Indicator securely stores test results on the free Menopause Stage -Clearblue me app. By taking five urine FSH tests every other day, the app can determine a woman's likely menopause stage.

Similarly, in 2022, Sugentech, a leading producer of digital ovulation test kits, formed a strategic partnership with CGETC, Inc., a U.S.-based company that specializes in consumer fulfillment and marketing services. The market features various digital devices equipped with advanced functionalities such as Bluetooth connectivity and smart countdown features. Prominent brands in this sector include Clearblue, First Response, and E.P.T.

Market Segmentation

By Product Type

Urine Ovulation Tests
- Ovulation Test Strips
- Ovulation Test Cassette (CE)
- Ovulation Midstream Tests
Saliva Ovulation Tests
Digital Ovulation Kit

By Distribution Channels

E-Commerce
Online & Retail Pharmacies
Hypermarkets & Supermarkets

By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the ovulation testing kits market include AdvaCare Pharma, Swiss Precision Diagnostics GmbH, Proov, PREGMATE, Easy@Home Fertility, Fairhaven Health, Ro, Piramal Pharma Ltd., Wondfo, and Accuquik Test Kits among others.

Key Developments

In June 2024, Mankind Pharma launched a new line of pregnancy care products in the Southern market, featuring celebrity Kajal Agarwal. The brand aims to expand its presence by offering essential pregnancy items, having experienced significant growth in regions like Karnataka. This new product line includes a comprehensive range of six curated items designed for the pre-, during-, and post-pregnancy phases, all supported by extensive research. The preconception phase includes the Ova News Ovulation Detection Kit which helps identify the five most fertile days in a woman's cycle, enhancing the chances of conception.

Why Purchase the Report?

To visualize the global ovulation testing kits market segmentation based on product type, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the ovulation testing kits market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global ovulation testing kits market report would provide approximately 54 tables, 42 figures, and 182 pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Distribution Channels
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Incidence of Fertility Disorders and Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of kits
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Urine Ovulation Tests *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Ovulation Test Strips
- 6.2.4. Ovulation Test Cassette (CE)
- 6.2.5. Ovulation Midstream Tests
6.3. Saliva Ovulation Tests
6.4. Digital Ovulation Kit

7. By Distribution Channels

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 7.1.2. Market Attractiveness Index, By Distribution Channels
7.2. E-Commerce*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Online & Retail Pharmacies
7.4. Hypermarkets & Supermarkets

8. By Region

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.5.1. The U.S.
  - 8.2.5.2. Canada
  - 8.2.5.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.5.1. Germany
  - 8.3.5.2. U.K.
  - 8.3.5.3. France
  - 8.3.5.4. Spain
  - 8.3.5.5. Italy
  - 8.3.5.6. Rest of Europe
8.4. South America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.6.1. Brazil
  - 8.4.6.2. Argentina
  - 8.4.6.3. Rest of South America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.5.1. China
  - 8.5.5.2. India
  - 8.5.5.3. Japan
  - 8.5.5.4. South Korea
  - 8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

9. Competitive Landscape

9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis

10. Company Profiles

10.1. AdvaCare Pharma *
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio and Description
- 10.1.3. Financial Overview
- 10.1.4. Key Developments
10.2. Swiss Precision Diagnostics GmbH
10.3. Proov
10.4. PREGMATE
10.5. Easy@Home Fertility
10.6. Fairhaven Health
10.7. Ro
10.8. Piramal Pharma Ltd.
10.9. Wondfo
10.10. Accuquik Test Kits (*LIST NOT EXHAUSTIVE)